Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 9/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31089812 | 0.88 | SCN9A (0.48) | SCN9A | |
| SCHEMBL21581584 | 0.88 | SCN9A (0.42) | AAK1SCN9AKDRBRAF | |
| SCHEMBL31089761 | 0.88 | SCN9A (0.42) | AAK1SCN9AKDRBRAF | |
| SCHEMBL29437978 | 0.84 | HDAC4 (0.41) | SCN9A | |
| SCHEMBL9923870 | 0.84 | HDAC4 (0.41) | SCN9A | |
| SCHEMBL12594163 | 0.84 | HDAC4 (0.41) | SCN9A | |
| SCHEMBL21611230 | 0.84 | AAK1 (0.39) | AAK1SCN9AKDR | |
| SCHEMBL21611234 | 0.83 | SCN9A (0.42) | AAK1SCN9A | |
| SCHEMBL21610275 | 0.81 | RAF1 (0.47) | RAF1AAK1MAPK3KDRMAP2K7 | |
| SCHEMBL21610277 | 0.81 | RAF1 (0.47) | RAF1AAK1MAPK3KDRMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | RAF1 2349/4885AAK1 2592/4885MAPK3 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.